Endocrine System Diseases  >>  AZD5658  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AZD5658 / AstraZeneca
NCT01176097: To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes

Completed
1
24
US
AZD5658, Placebo
AstraZeneca
Type 2 Diabetes
02/11
02/11

Download Options